Go Pro
NASDAQ:DXR

Daxor Q2 2026 Earnings Report

Daxor logo
$10.16 -0.13 (-1.21%)
As of 03:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Daxor EPS Results

Actual EPS
N/A
Consensus EPS
-$0.11
Beat/Miss
N/A
One Year Ago EPS
N/A

Daxor Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.90 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Daxor Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Daxor Earnings Headlines

Daxor (DXR) to Announce Quarterly Earnings on Thursday
Daxor (DXR) Stock Forecast & Price Target
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Daxor Launches Blood Testing Lab in Eastern Kansis
See More Daxor Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daxor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daxor and other key companies, straight to your email.

About Daxor

Daxor (NASDAQ:DXR) is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. The company offers training and technical support to hospital laboratories and specialty clinics, ensuring that staff are properly instructed in isotope handling, system operation and result interpretation. Through ongoing research collaborations, Daxor continuously evaluates new protocols and software enhancements to improve diagnostic performance and workflow efficiency.

Headquartered in New York, Daxor serves healthcare providers in North America and has established distribution partnerships in Europe, Asia‐Pacific and select emerging markets. Its solutions are used by major university medical centers, community hospitals and research institutions to inform decisions on blood transfusion, fluid management and therapeutic intervention. The company’s management team brings decades of experience in medical technology commercialization, regulatory affairs and laboratory operations, positioning Daxor to expand its global footprint and address evolving needs in patient blood management.

View Daxor Profile